Lead Product(s): IMU-856
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Immunic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.